Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Biomarker in Tissue Samples From Patients With Ewing Sarcoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group Identifier:
First received: June 1, 2011
Last updated: July 7, 2016
Last verified: July 2016

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in tissue samples from patients with Ewing sarcoma.

Condition Intervention
Genetic: microarray analysis
Genetic: protein analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: INI-1 Deletions in Ewing Sarcoma

Resource links provided by NLM:

Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Frequency of INI1 protein loss in Ewing Sarcoma [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Estimated Enrollment: 40
Study Start Date: May 2011
Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Detailed Description:


  • To determine the frequency of INI-1 protein loss in Ewing Sarcoma.

OUTLINE: Previously collected tissue samples are analyzed for INI-1 protein loss by IHC and tissue microarray.


Ages Eligible for Study:   up to 120 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diagnosis of Ewing sarcoma.


  • Diagnosis of Ewing sarcoma
  • Prepared tissue microarray with Ewing sarcoma samples available


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01365949

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Joshua D. Schiffman, MD University of Utah
  More Information

Responsible Party: Children's Oncology Group Identifier: NCT01365949     History of Changes
Other Study ID Numbers: AEWS11B1  COG-AEWS11B1  NCI-2011-02857  AEWS11B1 
Study First Received: June 1, 2011
Last Updated: July 7, 2016
Health Authority: United States: Federal Government

Keywords provided by Children's Oncology Group:
Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET)

Additional relevant MeSH terms:
Sarcoma, Ewing
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue processed this record on October 21, 2016